$36.86
+0.84 (+2.33%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IMCR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 1 expanded access · 5 with posted results
Held by 14 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., MARSHALL WACE, LLP, +9 more) · FINRA short interest 17.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of IMC-S118AI in Type 1 DiabetesNCT07493122Number of participants with ≥1 treatment-emergent serious adverse event (SAE)Randomized · Single-masked · Treatment | Phase 1 | Not yet recruiting | Biological: IMC-S118AI | Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1 | 154 | Nov 2030 | ≤ 1,563 d | 2026-03-25 |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)NCT05549297Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice | Advanced Melanoma | 540 | Mar 2028 | ≤ 589 d | 2026-02-25 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314Progression-Free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Brenetafusp, Nivolumab, Nivolumab + Relatlimab | Advanced Melanoma | 680 | 2027-10-16 | in 422 d | 2026-02-25 |
| Study of IMC-P115C in Advanced PRAME-Positive CancersNCT07156136Percentage of participants with dose-limiting toxicities (DLT)Open-label · Treatment | Phase 1 | Recruiting | Drug: IMC-P115C | PRAME Positive, Cancer, HLA-A*02:01-positive | 140 | 2027-09-30 | in 406 d | 2026-02-25 |
| Phase 1/2 Study of IMC-R117C in Selected Advanced CancersNCT06840119Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: IMC-R117C, Chemotherapy drug, Chemotherapy drug, Kinase inhibitor, Antiangiogenic Agent, Monoclonal antibody | Cancer, HLA-A*02:01-positive | 600 | 2026-11-30 | in 102 d | 2026-01-28 |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsNCT04262466Phase 1: Incidence of dose-limiting toxicity (DLT)sNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors | Select Advanced Solid Tumors | 410 | Oct 2026 | ≤ 72 d | 2026-03-06 |
| Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV InfectionNCT05867056Parts 1, 2, and 3: Incidence and treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Enrollment into the phase 2 portion was never initiated. | Drug: IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD | Hepatitis B, Chronic | 0 | 2024-09-10 | — | 2024-10-15 |
| Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabNCT03973333Phase 1: Incidence of dose-limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Study withdrawn by Sponsor | Drug: IMC-C103C, Atezolizumab, IMC-C103C | Select Advanced Solid Tumors | 0 | 2023-09-25 | — | 2024-10-18 |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaNCT02535078Phase 2: Objective Response Rate (ORR)Open-label · Treatment | Phase 1/2 | Withdrawn | Drug: Tebentafusp (IMCgp100) | Malignant Melanoma | 0 | 2023-06-19actual | — | 2024-07-24 |
| Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive CancersNCT03515551results2022-03-11Phase 1: Number of Participants With Dose-limiting ToxicitiesNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Strategic decision to stop development and not based on any safety concerns | Drug: IMCnyeso | Select Advanced Solid Tumors | 29 | 2021-05-10actual | — | 2022-03-11 |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392results2021-09-14Efficacy: Overall SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: IMCgp100, Ipilimumab, Pembrolizumab · Drug: Dacarbazine | Uveal Melanoma | 378 | 2020-10-13actual | — | 2026-03-17 |
| A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal MelanomaNCT02570308results2021-09-01Number of Participants With a Dose Limiting Toxicity (DLT) in Phase 1Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: IMCgp100 | Uveal Melanoma | 146 | 2020-03-20actual | — | 2023-03-21 |
| IMCgp100-401 Rollover StudyNCT02889861results2020-07-27Incidence of Adverse Events: Number of Participants With Treatment-Emergent Adverse EventsOpen-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: IMCgp100 | Malignant Melanoma | 3 | 2019-04-22actual | — | 2020-07-27 |
| Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant MelanomaNCT01211262results2020-07-08Maximum Tolerated Dose (MTD) of IMCgp100 Administered Weekly (Dose Escalation Part)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: IMCgp100 | Malignant Melanoma | 84 | 2016-02-16actual | — | 2020-07-08 |
| A Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspNCT04960891expanded access | — | Available | Drug: Tebentafusp | Uveal Melanoma | — | — | — | 2022-01-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19